Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term study of human-cl recombinant human factor VIII (rhFVIII) in previously treated patients with severe haemophilia A (GENA-11)
2010-023242-69Phase 3Completed
- Sponsor
- Octapharma
- Start
- Feb 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of simoctocog alfa in hemophilia A, sponsored by Octapharma. Primary endpoints: Long-term safety and tolerability, Long-term immunogenicity and 2 more. Started Feb 2011; status: completed.
02
Drugs
simoctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2010-023242-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023242-69.